Cargando…
Characteristics and Management of Patients with Refractory or Unexplained Chronic Cough in Outpatient Hospital Clinics in Spain: A Retrospective Multicenter Study
PURPOSE: Chronic cough (cough that persists for ≥ 8 weeks) can cause a range of physical symptoms and psychosocial effects that significantly impair patients’ quality of life. Refractory chronic cough (RCC) and unexplained chronic cough (UCC) are challenging to diagnose and manage, with substantial...
Autores principales: | Dávila, Ignacio, Puente, Luis, Quirce, Santiago, Arismendi, Ebymar, Díaz-Palacios, Miguel, Pereira-Vega, Antonio, de Diego, Alfredo, Rodriguez-Hermosa, Juan Luis, Cea-Calvo, Luis, Sánchez-Jareño, Marta, López-Cotarelo, Pilar, Domingo, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169201/ https://www.ncbi.nlm.nih.gov/pubmed/37160771 http://dx.doi.org/10.1007/s00408-023-00620-y |
Ejemplares similares
-
A Survey of Physicians' Perception of the Use and Effectiveness of Diagnostic and Therapeutic Procedures in Chronic Cough Patients
por: Puente-Maestu, Luis, et al.
Publicado: (2021) -
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
por: Dicpinigaitis, Peter V., et al.
Publicado: (2023) -
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
por: Morice, Alyn H., et al.
Publicado: (2021) -
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2022) -
Burden of refractory and unexplained chronic cough on patients’ lives: a cohort study
por: Puente-Maestu, Luis, et al.
Publicado: (2023)